On Friday, Shares of Ford Motor Co. (NYSE:F), gained 0.48% to $14.78.
Ford Motor Company declared it will assemble its popular Ford Ranger pickup truck in Nigeria starting in the fourth quarter of 2015 as part of its expansion in Middle East and Africa. Nigeria will be the first African country outside of South Africa where Ford vehicles are produced.
Ranger assembly will start in Ikeja, in the Lagos State about 750 km southwest of Nigeria’s capital city Abuja. Ford is partnering with Ford dealer group Coscharis Motors Limited on the project.
Ford will assemble the vehicles at a semi-knockdown level, using body parts and components imported from South Africa for the new Ranger. The new assembly plant in Ikeja will create about 180 jobs directly and indirectly, and has the capacity to assemble up to 5,000 units annually. Vehicles assembled at Ikeja are destined for sale in Nigeria only.
Ford Motor Company manufactures and distributes automobiles worldwide. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services vehicles, parts, and accessories.
Shares of Novavax, Inc. (NASDAQ:NVAX), declined -1.04% to $13.30, during its last trading session.
Novavax declared its financial results for the second quarter and six months ended June 30, 2015.
Novavax Second Quarter and Subsequent Achievements:
- Declared positive top-line data from a Phase 2 trial of its RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults. The trial demonstrated statistically noteworthyvaccine efficacy in the prevention of symptomatic RSV disease in older adults, the first vaccine to demonstrate efficacy against RSV disease in any population. The trial detected an attack rate of 4.9% for symptomatic RSV disease in 1,600 older adults. Similar to the Company’s findings in preceding trials, there were greater than four-fold enhances in both anti-F IgG and palivizumab-competing antibody (PCA) concentrations with serological responses in over 90% of vaccinated participants.
- Declared positive top-line data from a Phase 2 trial of its recombinant quadrivalent seasonal influenza virus-like particle candidate (Quadrivalent Seasonal Influenza VLP). The trial, funded in whole or part with Federal funds from the Company’s contract with HHS BARDA, demonstrated that the Quadrivalent Seasonal Influenza VLP vaccine candidate was well-tolerated with no vaccine-related serious adverse events. The trial met its immunogenicity targets and demonstrated potential to meet the Center for Biological Evaluation and Research (CBER) criteria for accelerated approval.
- Delivered positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine (Ebola GP Vaccine) candidate adjuvanted with Matrix-M™. The trial demonstrated that the adjuvanted Ebola GP Vaccine was highly immunogenic, well-tolerated and resulted in noteworthy antigen dose-sparing.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
Finally, Tronox Limited (NYSE:TROX), ended its last trade with 0.88% gain, and closed at $8.97.
Tronox Limited stated second quarter 2015 revenue of $617 million contrast to $490 million in the second quarter 2014 and $385 million in the first quarter 2015. Adjusted EBITDA was $116 million, not taking into account $49 million of net lower of cost or market (LCM) charges, contrast to $103 million, not taking into account net non-cash LCM credits of $5 million, in the year-ago quarter and $73 million, not taking into account net non-cash LCM charges of $9 million, in the preceding quarter. Adjusted net loss attributable to Tronox Limited in the second quarter was $81 million, or $0.70 per diluted share, as compared to breakeven net income, or $0.00 per diluted share, in the year-ago quarter and a loss of $51 million, or $0.44 per diluted share, in the first quarter 2015.
Tronox Limited produces and markets titanium bearing mineral sands and titanium dioxide (TiO2) pigment in North America, Europe, South Africa, and the Asia-Pacific region. It primarily operates in two segments, Mineral Sands and Pigment.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
